التفاصيل البيبلوغرافية
| العنوان: |
Potentiators exert distinct effects on human, murine, and Xenopus CFTR. |
| المؤلفون: |
Guiying Cui, Khazanov, Netaly, Stauffer, Brandon B., Infield, Daniel T., Imhoff, Barry R., Senderowitz, Hanoch, McCarty, Nael A. |
| المصدر: |
American Journal of Physiology: Lung Cellular & Molecular Physiology; Aug2016, Vol. 311 Issue 2, pL192-L207, 16p |
| مصطلحات موضوعية: |
CYSTIC fibrosis transmembrane conductance regulator, CYSTIC fibrosis treatment, GENETIC mutation, BINDING sites, BIOCHEMICAL mechanism of action |
| مستخلص: |
VX-770 (Ivacaftor) has been approved for clinical usage in cystic fibrosis patients with several CFTR mutations. Yet the binding site(s) on CFTR for this compound and other small molecule potentiators are unknown. We hypothesize that insight into this question could be gained by comparing the effect of potentiators on CFTR channels from different origins, e.g., human, mouse, and Xenopus (frog). In the present study, we combined this comparative molecular pharmacology approach with that of computer- aided drug discovery to identify and characterize new potentiators of CFTR and to explore possible mechanism of action. Our results demonstrate that 1) VX-770, NPPB, GlyH-101, P1, P2, and P3 all exhibited ortholog-specific behavior in that they potentiated hCFTR, mCFTR, and xCFTR with different efficacies; 2) P1, P2, and P3 potentiated hCFTR in excised macropatches in a manner dependent on the degree of PKA-mediated stimulation; 3) P1 and P2 did not have additive effects, suggesting that these compounds might share binding sites. Also 4) using a pharmacophore modeling approach, we identified three new potentiators (IOWH-032, OSSK-2, and OSSK-3) that have structures similar to GlyH-101 and that also exhibit orthologspecific potentiation of CFTR. These could potentially serve as lead compounds for development of new drugs for the treatment of cystic fibrosis. The ortholog-specific behavior of these compounds suggest that a comparative pharmacology approach, using cross-ortholog chimeras, may be useful for identification of binding sites on human CFTR. [ABSTRACT FROM AUTHOR] |
|
Copyright of American Journal of Physiology: Lung Cellular & Molecular Physiology is the property of American Physiological Society and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder